Evidence map›Paper›PMID 33815322›Full record

ArticleFrontiers in microbiology2021

A Therapeutic Strategy to Combat HIV-1 Latently Infected Cells With a Combination of Latency-Reversing Agents Containing DAG-Lactone PKC Activators.

Kouki Matsuda, Takuya Kobayakawa, Ryusho Kariya, Kiyoto Tsuchiya, Shoraku Ryu, Kohei Tsuji, Takahiro Ishii, Hiroyuki Gatanaga, Kazuhisa Yoshimura, Seiji Okada and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. HIV Reservoirs and Treatment Strategies toward Curing HIV Infection.International journal of molecular sciences · 2024
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Kouki MatsudaNational Center for Global Health and Medicine Research Institute, Tokyo, Japan.
Takuya KobayakawaInstitute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Bunkyō, Japan.
Ryusho KariyaDivision of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
Kiyoto TsuchiyaAIDS Clinical Center, National Center for Global Health and Medicine, Shinjuku, Japan.
Shoraku RyuDivision of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan.
Kohei TsujiInstitute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Bunkyō, Japan.
Takahiro IshiiInstitute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Bunkyō, Japan.
Hiroyuki GatanagaAIDS Clinical Center, National Center for Global Health and Medicine, Shinjuku, Japan.
Kazuhisa YoshimuraAIDS Research Centre, National Institute of Infectious Diseases, Tokyo, Japan.
Seiji OkadaDivision of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
Akinobu HamadaDivision of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan.
Hiroaki MitsuyaNational Center for Global Health and Medicine Research Institute, Tokyo, Japan.
Hirokazu TamamuraInstitute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Bunkyō, Japan.
Kenji MaedaNational Center for Global Health and Medicine Research Institute, Tokyo, Japan.
National Center for Global Health and Medicine · JPTokyo Medical and Dental University · JPKumamoto University · JPTokyo Metropolitan Institute of Public Health · JP

Funding

Development of Antiviral Therapy of HIV-1 InfectionZIASC006738 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI MITSUYA, HIROAKI · 2009 to 2025
$10.0M
6 · The paper itself

Abstract

Advances in antiviral therapy have dramatically improved the therapeutic effects on HIV type 1 (HIV-1) infection. However, even with potent combined antiretroviral therapy, HIV-1 latently infected cells cannot be fully eradicated. Latency-reversing agents (LRAs) are considered a potential tool for eliminating such cells; however, recent

Indexed as

diacylglycerol-lactoneHIV-1HIV-1 latently infected cellsHIV-1 reservoirsprotein kinase C activator

Identifiers

PMID33815322
PMCPMC8010149
OpenAlexW3136278721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.